Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.

Coltro G, Lasho TL, Finke CM, Gangat N, Pardanani A, Tefferi A, Jevremovic D, Altman JK, Patnaik MM.

Am J Hematol. 2019 Jun 7. doi: 10.1002/ajh.25552. [Epub ahead of print] No abstract available.

PMID:
31173385
2.

Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis.

Gangat N, Marinaccio C, Swords R, Watts JM, Gurbuxani S, Rademaker A, Fought AJ, Frankfurt O, Altman JK, Wen QJ, Farnoud N, Famulare CA, Patel A, Tapia R, Vallapureddy RR, Barath S, Graf A, Handlogten A, Zblewski D, Patnaik MM, Al-Kali A, Dinh YT, Englund Prahl K, Patel S, Nobrega JC, Tejera D, Thomassen A, Gao J, Ji P, Rampal RK, Giles FJ, Tefferi A, Stein B, Crispino JD.

Clin Cancer Res. 2019 May 6. doi: 10.1158/1078-0432.CCR-19-1005. [Epub ahead of print]

PMID:
31061068
3.
4.

Proposed diagnostic criteria for classical CMML, CMML variants and pre-CMML conditions.

Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lubbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstocker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM.

Haematologica. 2019 May 2. pii: haematol.2019.222059. doi: 10.3324/haematol.2019.222059. [Epub ahead of print]

5.

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.

Goyal G, Ravindran A, Young JR, Shah MV, Bennani NN, Patnaik MM, Nowakowski GS, Thanarajasingam G, Habermann TM, Vassallo R, Sher T, Parikh SA, Rech KL, Go RS; Mayo Clinic Histiocytosis Working Group.

Haematologica. 2019 Apr 19. pii: haematol.2019.219626. doi: 10.3324/haematol.2019.219626. [Epub ahead of print]

6.

Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.

Coston T, Pophali P, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, Carr R, Binder M, Mangaonkar AA, Gangat N, Al-Kali A, Litzow M, Zblewski D, Pardanani A, Tefferi A, Patnaik MM.

Am J Hematol. 2019 Jul;94(7):767-779. doi: 10.1002/ajh.25488. Epub 2019 May 3.

PMID:
30964202
7.

Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia.

Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, Kosmider O, Pierron G, Fernandez-Zapico ME, Howard MT, King RL, Niyongere S, Diop MK, Fenaux P, Itzykson R, Willekens C, Ribrag V, Fontenay M, Padron E, Soumelis V, Droin N, Patnaik MM, Solary E.

Leukemia. 2019 Mar 20. doi: 10.1038/s41375-019-0447-3. [Epub ahead of print]

PMID:
30894665
8.

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.

Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Begna KH, Elliott MA, Hook CC, Wolanskyj AP, Patnaik MM, Hanson CA, Ketterling RP, Sirhan S, Pardanani A, Gangat N, Busque L, Tefferi A.

Mayo Clin Proc. 2019 Apr;94(4):599-610. doi: 10.1016/j.mayocp.2018.08.022. Epub 2019 Feb 26.

PMID:
30824279
9.

Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant.

Higgins A, Khan Z, Coddington CC, Hashmi SK, Hefazi M, Alkhateeb H, Litzow MR, Hogan WJ, Cathcart-Rake E, Thompson CA, Patnaik MM.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1232-1239. doi: 10.1016/j.bbmt.2019.02.013. Epub 2019 Feb 15.

PMID:
30772513
10.

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.

Gangat N, Phelps A, Lasho TL, Finke CM, Vallapureddy R, Hanson CA, Ketterling RP, Patnaik MM, Pardanani A, Tefferi A.

Blood Cancer J. 2019 Jan 24;9(2):11. doi: 10.1038/s41408-018-0167-3. No abstract available.

11.

Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".

Patnaik MM, Tefferi A.

Am J Hematol. 2019 Apr;94(4):475-488. doi: 10.1002/ajh.25397. Epub 2019 Jan 24.

PMID:
30618061
12.

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation.

Patnaik MM, Pophali PA, Lasho TL, Finke CM, Horna P, Ketterling RP, Gangat N, Mangaonkar AA, Pardanani A, Tefferi A.

Haematologica. 2019 Jun;104(6):e236-e239. doi: 10.3324/haematol.2018.208082. Epub 2019 Jan 3. No abstract available.

13.

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.

Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS.

Blood. 2019 Feb 14;133(7):697-709. doi: 10.1182/blood-2018-10-881722. Epub 2018 Nov 21.

PMID:
30463995
14.

Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.

Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, Patnaik MM, Gangat N, Ketterling RP, Reichard KK, Hanson CA, Vannucchi AM, Tefferi A.

Blood Adv. 2018 Nov 13;2(21):2964-2972. doi: 10.1182/bloodadvances.2018026245.

15.

Novel germline missense DDX41 variant in a patient with an adult-onset myeloid neoplasm with excess blasts without dysplasia.

Vairo FPE, Ferrer A, Cathcart-Rake E, King RL, Howard MT, Viswanatha DS, Klee EW, Mangaonkar AA, Patnaik MM.

Leuk Lymphoma. 2019 May;60(5):1337-1339. doi: 10.1080/10428194.2018.1522443. Epub 2018 Nov 8. No abstract available.

PMID:
30407884
16.

In Reply-Short Telomere Syndromes, Biological Aging, and Hematopoietic Stem Cell Transplantation.

Mangaonkar AA, Patnaik MM.

Mayo Clin Proc. 2018 Nov;93(11):1685-1687. doi: 10.1016/j.mayocp.2018.08.012. No abstract available.

PMID:
30392550
17.

Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients.

Miller KC, Al-Kali A, Shah MV, Hogan WJ, Elliott MA, Begna KH, Gangat N, Patnaik MM, Viswanatha DS, He R, Greipp PT, Sproat LZ, Foran JM, Litzow MR, Alkhateeb HB.

Leuk Lymphoma. 2019 Apr;60(4):990-999. doi: 10.1080/10428194.2018.1509318. Epub 2018 Oct 2.

PMID:
30277111
18.

45-Year-Old Man With Abdominal Pain and Splenomegaly.

Gast KC, Hoversten K, Patnaik MM.

Mayo Clin Proc. 2018 Nov;93(11):e113-e117. doi: 10.1016/j.mayocp.2018.02.028. Epub 2018 Sep 27. No abstract available.

PMID:
30269944
19.

Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.

Tefferi A, Szuber N, Vallapureddy RR, Begna KH, Patnaik MM, Elliott MA, Christopher Hook C, Wolanskyj AP, Hanson CA, Ketterling RP, Pardanani A, Gangat N.

Am J Hematol. 2019 Jan;94(1):5-9. doi: 10.1002/ajh.25294. Epub 2018 Oct 17.

PMID:
30252953
20.

A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status.

Begna KH, Ali W, Gangat N, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, Chen D, He R, Viswanatha D, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 Dec;93(12):E401-E404. doi: 10.1002/ajh.25290. Epub 2018 Oct 17. No abstract available.

PMID:
30230610
21.

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms.

Patnaik MM, Lasho T, Howard M, Finke C, Ketterling RL, Al-Kali A, Pardanani A, Droin N, Gangat N, Tefferi A, Solary E.

Blood Cancer J. 2018 Aug 22;8(9):82. doi: 10.1038/s41408-018-0120-5. No abstract available.

22.

Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic target.

Mangaonkar AA, Patnaik MM, Oliver GR, Rao KW, Kaiser-Rogers K, Davila JI, Fadra N, Wehrs RN, Elliott MA, Greipp PT, Halling KC, Van Dyke DL.

Leuk Lymphoma. 2019 Mar;60(3):821-824. doi: 10.1080/10428194.2018.1498492. Epub 2018 Aug 30. No abstract available.

PMID:
30160574
23.

Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm.

Tefferi A, Shah S, Lasho TL, Patnaik MM, Reichard KK, Hanson CA, Ketterling RP, Pardanani A.

Am J Hematol. 2018 Dec;93(12):E383-E386. doi: 10.1002/ajh.25269. Epub 2018 Oct 17. No abstract available.

PMID:
30156701
24.

Mutations and karyotype predict treatment response in myelodysplastic syndromes.

Idossa D, Lasho TL, Finke CM, Ketterling RP, Patnaik MM, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Nov;93(11):1420-1426. doi: 10.1002/ajh.25267. Epub 2018 Sep 30.

PMID:
30152885
25.

Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases.

Shah S, Pardanani A, Elala YC, Lasho TL, Patnaik MM, Reichard KK, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 Dec;93(12):1461-1466. doi: 10.1002/ajh.25265. Epub 2018 Sep 26.

PMID:
30152525
26.

Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients.

Pophali P, Horna P, Lasho TL, Finke CM, Ketterling RP, Gangat N, Nagorney D, Tefferi A, Patnaik MM.

Am J Hematol. 2018 Nov;93(11):1347-1357. doi: 10.1002/ajh.25246. Epub 2018 Oct 5.

PMID:
30105755
27.

Blast-phase chronic myelomonocytic leukemia: more than just semantics.

Patnaik MM, Tefferi A, Garcia-Manero G.

Leukemia. 2018 Sep;32(9):2093-2094. doi: 10.1038/s41375-018-0228-4. Epub 2018 Aug 7. No abstract available.

PMID:
30087420
28.

Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia.

Nazha A, Patnaik MM.

Curr Hematol Malig Rep. 2018 Oct;13(5):341-347. doi: 10.1007/s11899-018-0465-7. Review.

PMID:
30066099
29.

Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts.

Mangaonkar AA, Gangat N, Al-Kali A, Elliott MA, Begna KH, Hanson CA, Ketterling RP, Wolanskyj-Spinner AP, Hogan WJ, Litzow MR, Patnaik MM.

Leuk Res. 2018 Aug;71:60-62. doi: 10.1016/j.leukres.2018.07.010. Epub 2018 Jul 11.

PMID:
30015104
30.

Clinical Correlates and Treatment Outcomes for Patients With Short Telomere Syndromes.

Mangaonkar AA, Ferrer A, Pinto E Vairo F, Cousin MA, Kuisle RJ, Klee EW, Kennedy CC, Peters SG, Scott JP, Utz JP, Baqir M, Sekiguchi H, Khan SP, Rodriguez V, Simonetto DA, Kamath PS, Abraham RS, Wylam ME, Patnaik MM.

Mayo Clin Proc. 2018 Jul;93(7):834-839. doi: 10.1016/j.mayocp.2018.05.015.

PMID:
29976374
31.

Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.

Patnaik MM, Tefferi A.

Am J Hematol. 2018 Jun;93(6):824-840. doi: 10.1002/ajh.25104. Review.

32.

Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information.

Tefferi A, Gangat N, Mudireddy M, Lasho TL, Finke C, Begna KH, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, He R, Viswanatha D, Hanson CA, Ketterling RP, Tang JL, Chou WC, Lin CC, Tsai CH, Tien HF, Hou HA.

Mayo Clin Proc. 2018 Oct;93(10):1363-1374. doi: 10.1016/j.mayocp.2018.04.013. Epub 2018 Jun 14.

PMID:
29866419
33.

Short Telomere Syndromes in Clinical Practice: Bridging Bench and Bedside.

Mangaonkar AA, Patnaik MM.

Mayo Clin Proc. 2018 Jul;93(7):904-916. doi: 10.1016/j.mayocp.2018.03.020. Epub 2018 May 24. Review.

PMID:
29804726
34.

Genotype-Phenotype Correlation of Hereditary Erythrocytosis Mutations, a single center experience.

Oliveira JL, Coon LM, Frederick LA, Hein M, Swanson KC, Savedra ME, Porter TR, Patnaik MM, Tefferi A, Pardanani A, Grebe SK, Viswanatha DS, Hoyer JD.

Am J Hematol. 2018 May 23. doi: 10.1002/ajh.25150. [Epub ahead of print]

35.

Hepatic manifestations of telomere biology disorders.

Patnaik MM, Kamath PS, Simonetto DA.

J Hepatol. 2018 Sep;69(3):736-743. doi: 10.1016/j.jhep.2018.05.006. Epub 2018 Jun 7. Review.

PMID:
29758336
36.

Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases.

Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, Kadia TM, Jabbour EJ, Lasho T, Hanson CA, Ketterling RP, Kantarjian HM, Tefferi A, Garcia-Manero G.

Leukemia. 2018 Nov;32(11):2512-2518. doi: 10.1038/s41375-018-0143-8. Epub 2018 Apr 25. No abstract available.

37.

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R.

EBioMedicine. 2018 May;31:174-181. doi: 10.1016/j.ebiom.2018.04.018. Epub 2018 Apr 25.

38.

A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.

Patnaik MM, Rangit Vallapureddy, Lasho TL, Hoversten KP, Finke CM, Ketterling RP, Hanson CA, Gangat N, Tefferi A, Pardanani A.

Leukemia. 2018 Aug;32(8):1850-1856. doi: 10.1038/s41375-018-0121-1. Epub 2018 Apr 2. No abstract available.

PMID:
29712989
39.

Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions.

Hefazi M, Langer KJ, Khera N, Adamski J, Roy V, Winters JL, Gastineau DA, Jacob EK, Kreuter JD, Gandhi MJ, Hogan WJ, Litzow MR, Hashmi SK, Yadav H, Iyer VN, Scott JP, Wylam ME, Cartin-Ceba R, Patnaik MM.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1906-1913. doi: 10.1016/j.bbmt.2018.04.012. Epub 2018 Apr 18.

PMID:
29679771
40.

Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates.

Hoversten K, Vallapureddy R, Lasho T, Finke C, Ketterling R, Hanson C, Gangat N, Tefferi A, Patnaik MM.

Leuk Lymphoma. 2018 Dec;59(12):2998-3001. doi: 10.1080/10428194.2018.1452212. Epub 2018 Mar 27. No abstract available.

PMID:
29582697
41.

SETD2 - linking stem cell survival and transformation.

Patnaik MM, Abdel-Wahab O.

Cell Res. 2018 Apr;28(4):393-394. doi: 10.1038/s41422-018-0025-7. No abstract available.

42.

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms.

Lasho TL, Vallapureddy R, Finke CM, Mangaonkar A, Gangat N, Ketterling R, Tefferi A, Patnaik MM.

Blood Cancer J. 2018 Mar 12;8(3):32. doi: 10.1038/s41408-018-0057-8. No abstract available.

43.

U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates.

Tefferi A, Mudireddy M, Finke CM, Nicolosi M, Lasho TL, Hanson CA, Patnaik MM, Pardanani A, Gangat N.

Am J Hematol. 2018 Jun;93(6):E146-E148. doi: 10.1002/ajh.25084. Epub 2018 Apr 6. No abstract available.

44.

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.

Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Szuber N, Begna KH, Patnaik MM, Gangat N, Pardanani A, Tefferi A.

Blood Adv. 2018 Feb 27;2(4):370-380. doi: 10.1182/bloodadvances.2018015875.

45.

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM.

Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y. Epub 2018 Feb 2.

46.

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts.

Mangaonkar AA, Lasho TL, Finke CM, Gangat N, Al-Kali A, Elliott MA, Begna KH, Alkhateeb H, Wolanskyj-Spinner AP, Hanson CA, Ketterling RP, Hogan WJ, Pardanani A, Litzow MR, Tefferi A, Patnaik MM.

Blood Cancer J. 2018 Feb 12;8(2):18. doi: 10.1038/s41408-018-0051-1. No abstract available.

47.

Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model.

Gangat N, Mudireddy M, Lasho TL, Finke CM, Nicolosi M, Szuber N, Patnaik MM, Pardanani A, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 May;93(5):691-697. doi: 10.1002/ajh.25064. Epub 2018 Feb 24.

48.

Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis.

Tefferi A, Partain DK, Palmer JM, Slack JL, Roy V, Hogan WJ, Litzow ML, Ketterling RP, Patnaik MM.

Am J Hematol. 2018 May;93(5):649-654. doi: 10.1002/ajh.25053. Epub 2018 Feb 24.

49.

FGFR1 rearranged hematological neoplasms - molecularly defined and clinically heterogeneous.

Patnaik MM, Ketterling RP, Tefferi A.

Leuk Lymphoma. 2018 Jul;59(7):1520-1522. doi: 10.1080/10428194.2018.1429607. Epub 2018 Jan 31. No abstract available.

PMID:
29384399
50.

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental.

Patnaik MM, Vallapureddy R, Lasho TL, Hoversten KP, Finke CM, Ketterling R, Hanson C, Gangat N, Tefferi A.

Blood Cancer J. 2018 Jan 22;8(1):12. doi: 10.1038/s41408-017-0045-4. No abstract available.

Supplemental Content

Loading ...
Support Center